Cover Image
市場調查報告書

伊波拉病毒染治療藥及疫苗全球市場的未來性分析(開發平台分析,藥物,疫苗,地區)

Global Potential Analysis of Ebola drug and Vaccines Market (Pipeline analysis, Drugs, Vaccines, and Geography) through 2020

出版商 Allied Market Research 商品編碼 316325
出版日期 內容資訊 英文 55 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
伊波拉病毒染治療藥及疫苗全球市場的未來性分析(開發平台分析,藥物,疫苗,地區) Global Potential Analysis of Ebola drug and Vaccines Market (Pipeline analysis, Drugs, Vaccines, and Geography) through 2020
出版日期: 2014年09月14日 內容資訊: 英文 55 Pages
簡介

以伊波拉出血熱(EHF)廣為人知的伊波拉病毒染(EVD)是與其他三種遺傳基因性密切相關的病毒(相關病毒屬)為病原的疾病,其初期症狀有喉嚨痛及頭痛、發燒、肌肉酸痛等。這會引發造成體內、體外出血的出血熱。這個疾病正在中、西非蔓延中,由於其具有高致死率,再加上沒有決定性可治療手法存在,因此可說是醫藥品廠商必須關注的莫大商機。

本報告以伊波拉病毒染的相關全球市場為焦點,除了依開發平台,治療藥·疫苗等產品,地區別探討今後發展的可能性,更彙整其趨勢,推動·阻礙因素,競爭環境,主要加入企業等相關的最新資訊。

第1章 簡介

  • 報告的主要優點
  • 報告的主要對象市場區隔
  • 報告的推薦用戶層
  • 調查方法

第2章 摘要整理

第3章 市場概要

  • 市場定義和範圍
  • 重要發現
    • 影響市場成長的主要系數
    • 主要資金來源
    • 主要成功策略
  • 主要打入市場企業的地位
  • 伊波拉病毒的重要事實
    • 伊波拉病毒的感染
    • 伊波拉病毒的徵兆與症狀
    • 伊波拉病毒的診斷法
    • 可以使用的伊波拉病毒治療藥和疫苗
  • 美國的伊波拉病毒治療藥的改良
    • 伊波拉病毒患者的航空醫療運輸指南
  • 美國政府提定對伊波拉病毒治療藥採取「快速審批」
  • ZMMP Drug:伊波拉病毒的稀少解決方案
  • 治療藥帶來的倫理困境
  • 美國食品藥物管理局(FDA)資金促進Tekmira Pharma加速伊波拉病毒研究
  • 臨床實驗
  • 市場動態
    • 推動要素
    • 阻礙因素
    • 機會

第4章 伊波拉病毒疫苗的預測方案分析(單位:100萬美元)

  • 穩定成長方案
  • 急速成長方案
  • 負成長方案

第5章 伊波拉病毒治療疫苗市場全球的開發平台及市場能力分析 - 地區別

  • 北美
  • 歐洲
  • 亞太地區
  • 中南美·中東·非洲

第6章 企業簡介(企業概要,簡述,財務成績,策略性動向及發展,SWOT分析等)

  • Tekmira Pharmaceuticals
  • BioCryst Pharmaceutical Inc.
  • Serepata Therapeutics
  • NewLink Genetics Corp.
  • Mapp Biopharmaceutical
目錄
Product Code: PH 14503

Ebola virus disease (EVD), also known as Ebola hemorrhagic fever (EHF), results from Ebola virus and three other closely related viruses in the genes (group of related viruses) of ebola virus. Initial symptoms of this disease include sore throat, headaches, fever and muscles pain. It causes hemorrhagic fever that leads to internal or external bleeding. EVD is widely prevalent in Central and Western Africa, and near tropical rainforests. Due to high mortality rate and unavailability of effective treatments, the pharmaceutical companies have big opportunities to explore. Tekmira Pharmaceuticals, BioCryst Pharmaceutical Inc., Serepata Therapeutics, NewLink Genetics and Mapp Biopharmaceutical are some of the leading companies focusing on research activities to develop efficacious medicine for EVD. Additionally, the governments in the developed countries have also taken formidable steps to support the research activities for the development of EVD therapeutics by providing funding and floating favorable policies. As an example, Tekmira Pharmaceuticals has received fast-track designation from U.S. food and drug administration for their anti-ebola therapeutic TKM-ebola. In 2012, Sarepta Therapeutics had also received fast track designation for AVI-7537, a lead drug candidate for EVD. Both these companies are developing their anti-ebola products under the contract of the U.S. department of defense (DoD).

Ebola therapeutics and vaccines market is segmented on the basis of geography into North America, Europe, Asia-pacific and LAMEA. EVD is rampant in LAMEA regions, specifically in African countries. This is a positive sign for pharmaceutical companies, portraying a highly lucrative market in the future. Earlier, US government did not have any regulations for EVD therapeutics due to negligible incidences of this disease in developed economies. However, preference of African people to migrate to developed economies rather than developing economies has cautioned the governments in the developed economies, leading to formulate regulations in order to curb the spread of this disease.

KEY BENEFITS

This report offers the following benefits in particular:

  • To track commercial trends, major clinical trials and their status are pursued of closely
  • The report sheds light on the key events held in past years concerning the development of ebola viral disease therapeutics
  • Pin-point analysis of geographic segments helps to identify opportunities for growth within the ebola therapeutics and vaccines market
  • Porter's Five Forces analysis examines the competitive structure of the ebola therapeutics and vaccines market and would assist market strategists in their respective decision making process
  • In-depth coverage of the ebola therapeutics and vaccines market including drivers, restraints and opportunities would help professionals to better understand market behavior
  • Detailed study of the strategies of key leaders, partnerships and acquisitions in the ebola therapeutics and vaccines market would be informative for professionals in corporate sector

KEY MARKET SEGMENTS

Ebola therapeutics and vaccines market is segmented on the basis of geography.

  • LAMEA
  • North America
  • Europe
  • Asia-Pacific

Table of Contents

CHAPTER 1 INTRODUCTION

  • 1.1 Key Benefits
  • 1.2 Key Market Segment
  • 1.3 Key Audiences
  • 1.4 Research Methodology
    • 1.4.1 Primary Research
    • 1.4.2 Secondary Research
    • 1.4.3 Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

CHAPTER 3 MARKET OVERVIEW

  • 3.1 Market Definition and Scope
  • 3.2 Key Findings
    • 3.2.1 Top factor impacting the market growth
    • 3.2.2 Top investment pockets
  • 3.3 Key market player positioning
  • 3.4 Ebola Virus Key Facts
    • 3.4.1 Transmission of Ebola
    • 3.4.2 Signs and symptoms of ebola
    • 3.4.3 Diagnosis of ebola
    • 3.4.4 Vaccine or treatment available for ebola
  • 3.5 Amend for anti-Ebola disease drugs in United States
  • 3.6 Guidance on Air Medical Transport for Patients with Ebola Virus Disease
  • 3.7 "Fast Track" designation to Anti-E bola drugs research from the U.S. government
  • 3.8 ZMMP Drug: An Orphan solution for E-bola viral disease
    • 3.8.1 ZMAPP is not ready for prime time
      • 3.8.1.1 Orphan Drugs for Orphan Diseases
  • 3.9 Ethical Dilemmas from therapeutics
  • 3.10 Tekmira Pharma received boost to ebola R&D through FDA fundings
  • 3.11 Clinical Trials
  • 3.12 Market Dynamics
    • 3.12.1 Drivers
      • 3.12.1.1 Prevalent cases and unpredictable nature of disease
      • 3.12.1.2 Increased rate of migration from developing countries
      • 3.12.1.3 Lack of relevant medication
    • 3.12.2 Restraints
      • 3.12.2.1 High initial investment for R&D
      • 3.12.2.2 Obstractive ethical considerations
    • 3.12.3 Opportunities
      • 3.12.3.1 Development of economic vaccines and drugs
      • 3.12.3.2 Gaining competitive edge in developing economies

CHAPTER 4 FORECASTE SCENARIO ANALYSIS OF EBOLA VACCINES, 2013-2020, ($MILLION)

  • 4.1 Moderate growth scenario
  • 4.2 Rapid growth scenario
  • 4.3 Diminishing growth scenario

CHAPTER 5 GLOBAL PIPELINE AND MARKET POTENTIAL ANALYSIS OF E-BOLA THERAPEUTIC VACCINES MARKET BY GEOGRAPHY, 2013 - 2020

  • 5.1 North America
  • 5.2 Europe
  • 5.3 Asia Pacific
  • 5.4 LAMEA

CHAPTER 6 COMPANY PROFILES

  • 6.1 Tekmira Pharmaceuticals
    • 6.1.1 Overview
    • 6.1.2 Company snapshot
    • 6.1.3 Financial performance
    • 6.1.4 Strategic moves and developments
    • 6.1.5 SWOT analysis
  • 6.2 BioCryst Pharmaceutical Inc.
    • 6.2.1 Overview
    • 6.2.2 Company snapshot of BioCryst Pharmaceutical Inc.
    • 6.2.3 Financial performance
    • 6.2.4 Strategic moves and developments
    • 6.2.5 SWOT analysis
  • 6.3 Serepata Therapeutics
    • 6.3.1 Overview
    • 6.3.2 Company snapshot
    • 6.3.3 Strategic moves and developments
    • 6.3.4 SWOT analysis
  • 6.4 NewLink Genetics Corp.
    • 6.4.1 Overview
    • 6.4.2 Company snapshot
    • 6.4.3 Financial performance
    • 6.4.4 Strategic moves and developments
    • 6.4.5 SWOT analysis
  • 6.5 Mapp Biopharmaceutical
    • 6.5.1 Overview
    • 6.5.2 Company snapshot
    • 6.5.3 Strategic moves and developments
    • 6.5.4 SWOT analysis of Mapp Biopharmaceutical

List of Tables

  • TABLE 1 CHRONOLOGY OF E-BOLA VIRUS INCIDENCE
  • TABLE 2 CLINICAL TRIAL NO I
  • TABLE 3 CLINICAL TRIAL NO II
  • TABLE 4 CLINICAL TRIAL NO III
  • TABLE 5 RAPID GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 (THOUSAND UNIT)
  • TABLE 6 RAPID GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 ($THOUSAND)
  • TABLE 7 MODERATE GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 (THOUSAND UNIT)
  • TABLE 8 MODERATE GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 ($THOUSAND)
  • TABLE 9 DIMINISHING GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 (THOUSAND UNIT)
  • TABLE 10 DIMINISHING GROWTH SCENARIO OF EBOLA VACCINES MARKET, 2013-2020 ($THOUSAND)
  • TABLE 11 GLOBAL EVD POTENTIAL VACCINES MARKET BY GEOGRAPHY, 2015-2020, (THOUSAND UNITS)
  • TABLE 14 GLOBAL EVD VACCINES DEMAND BY GEOGRAPHY, 2015-2020, (UNITS IN THOUSAND)
  • TABLE 15 COMPANY SNAPSHOT OF TEKMIRA PHARMACEUTICALS
  • TABLE 16 COMPANY SNAPSHOT OF BIOCRYST PHARMACEUTICAL INC.
  • TABLE 17 COMPANY SNAPSHOT OF SEREPATA THERAPEUTICS
  • TABLE 18 COMPANY SNAPSHOT OF NEWLINK GENETICS CORP.
  • TABLE 19 COMPANY SNAPSHOT OF MAPP BIOPHARMACEUTICAL

List of Figures

  • FIG. 1 TOP IMPACTING FACTORS OF EBOLA VIRAL DISEASE DRUGS (2013-2020)
  • FIG. 2 TOP INVESTMENT POCKETS
  • FIG. 3 KEY MARKET PLAYER POSITIONING OF EBOLA THERAPEUTICS
  • FIG. 4 MILESTONE OF E-BOLA DISEASE PREVALENCE BY GEOGRAPHIES
  • FIG. 5 SURGED EBOLA INCIDENCES IN WEST AFRICA (2014)
  • FIG. 6 TEKMIRA'S NET REVENUE FROM RESEARCH COLLABORATIONS AND CONTRACTS (2013)
  • FIG. 7 SWOT ANALYSIS OF TEKMIRA PHARMACEUTICALS
  • FIG. 8 R&D EXPENSES OF BIOCRYST PHARMACEUTICAL INC. (2013)
  • FIG. 9 SWOT ANALYSIS OF BIOCRYST PHARMACEUTICAL INC.
  • FIG. 10 SWOT ANALYSIS OF SEREPATA THERAPEUTICS
  • FIG. 11 RESEARCH AND DEVELOPMENT EXPENSES BY PRODUCTS (2013)
  • FIG. 12 SWOT ANALYSIS OF NEWLINK GENETICS CORP.
  • FIG. 13 SWOT ANALYSIS OF MAPP BIOPHARMACEUTICAL
Back to Top